Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Parkinson's Disease
Interventions: FB-101, Placebo; Drug
Lead sponsor: 1ST Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: TOL-3021, TOL-3021 Placebo; Biological · Other
Lead sponsor: Tolerion, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • San Mateo, California + 20 more

Conditions: Chronic Heart Failure With Preserved Ejection Fraction
Interventions: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 29
States / cities: Beverly Hills, California • Carmichael, California • West Hills, California + 26 more

Conditions: End-Stage Renal Disease
Interventions: Anakinra, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Immune globulin (human) 10% solution for intravenous administration; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Stamford, Connecticut • Miami, Florida • Pembroke Pines, Florida + 3 more

Conditions: Dyslipidemia
Interventions: LCP-AtorFen, atorvastatin, fenofibrate; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Newly Diagnosed Glioblastoma
Interventions: Nivolumab, Relatlimab, TMZ, Radiation Therapy; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Houston, Texas

Conditions: Neoplasms
Interventions: BXQ-350; Drug
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Lexington, Kentucky • Cincinnati, Ohio • Columbus, Ohio

Conditions: Ulcerative Colitis
Interventions: BI 3032950 intravenous (Part A), BI 3032950 subcutaneous (Part B); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: Scottsdale, Arizona • Colorado Springs, Colorado • Kissimmee, Florida + 10 more

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more

Conditions: Healthy Adult
Interventions: [¹⁸F]MODAG-009 PET Imaging; Drug
Lead sponsor: MODAG GmbH; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Abemaciclib, Atezolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: HBI-002, Vehicle (placebo); Drug
Lead sponsor: Hillhurst Biopharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Fountain Valley, California • Gainesville, Florida • Boston, Massachusetts + 5 more

Conditions: Covid19 Pneumonia
Interventions: EC-18, Placebo; Drug
Lead sponsor: Enzychem Lifesciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: The Bronx, New York • Warwick, Rhode Island

Conditions: Neuroblastoma
Interventions: 18F-MFBG; Drug
Lead sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC); Industry
Eligibility: Not listed
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxins, Type A, Placebos; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more

Conditions: Liver Fibroses, Cirrhosis
Interventions: Atorvastatin 20mg, Placebo; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Heart Failure
Interventions: Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 14
States / cities: Dothan, Alabama • Huntsville, Alabama • Inverness, Florida + 11 more

Conditions: Stable Coronary Artery Disease
Interventions: Selatogrel, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Advanced Cancer
Interventions: Interview, Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: PF-03463275, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 37
States / cities: Cerritos, California • Chula Vista, California • Escondido, California + 26 more

Conditions: Type 2 Diabetes
Interventions: ITCA 650, glimepiride; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hayward, California

Conditions: Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line, First-Line, Initial Therapy
Interventions: Lenalidomide and Rituximab; Drug
Lead sponsor: Chronic Lymphocytic Leukemia Research Consortium; Network
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: La Jolla, California • Boston, Massachusetts • New Hyde Park, New York + 2 more

Conditions: Leukemia
Interventions: recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, imatinib mesylate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Duarte, California • Seattle, Washington

Search by objective public record fields.

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

Anti-Cytokine Therapy for Hemodialysis InflammatION

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

Continued Treatment for Participants Enrolled in Studies of BXQ-350

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers

Abemaciclib With or Without Atezolizumab for mCRPC

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Patient and Family Decision Making in the Palliative Care Setting

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia